Xie Yujia, Lin Shaoqing, Guo Liping, Qi Xinru, Zhao Shiqi, Pei Qichuan, Chen Yixiao, Wu Qi, Wang Yun, Yao Meixue, Yin Dehui
Jiangsu Engineering Research Center of Biological Data Mining and Healthcare Transformation, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Medical Research Center and Clinical Laboratory, Zhuhai People's Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai, China.
Front Microbiol. 2025 Jan 3;15:1516915. doi: 10.3389/fmicb.2024.1516915. eCollection 2024.
Timely and accurate diagnosis is crucial for the effective treatment and prevention of brucellosis. Current serological diagnostics, primarily based on lipopolysaccharide (LPS), suffer from cross-reactivity with other Gram-negative bacteria, which limits their specificity. Periplasmic protein 26 (BP26), a highly immunogenic antigen found in , has emerged as a promising alternative for enhancing diagnostic specificity. This study aimed to develop and evaluate a competitive enzyme-linked immunosorbent assay (C-ELISA) utilizing monoclonal antibodies against BP26 for the diagnosis of human brucellosis, thereby providing a more accurate and specific diagnostic approach.
The study produced monoclonal antibody (mAb) against the BP26 protein through traditional mouse hybridoma technology and developed the C-ELISA method, and compared with a C-ELISA method based on LPS mAb. The detection performance was validated through the analysis of 190 human serum samples, which included 95 brucellosis serum samples and 95 negative serum samples collected by the Xuzhou Center for Disease Control and Prevention, and a comparative analysis was conducted on the diagnostic efficacy of indirect ELISA for brucellosis using both BP26 and LPS-based methods.
The BP26 mAb based C-ELISA achieved 100% sensitivity and specificity in detecting human brucellosis, significantly outperforming the C-ELISA based LPS mAb. Furthermore, the accuracy of the indirect enzyme-linked immunosorbent assay (I-ELISA) using BP26 protein was 98.95%, compared to an accuracy of LPS diagnosis was 99.47%. These results indicated that the BP26 mAb can effectively and accurately detected human brucellosis infections.
This study successfully developed and evaluated a BP26 protein-based C-ELISA method for diagnosing human brucellosis, establishing a foundation for identifying alternative diagnostic antigens for brucellosis.
及时准确的诊断对于布鲁氏菌病的有效治疗和预防至关重要。目前主要基于脂多糖(LPS)的血清学诊断方法存在与其他革兰氏阴性菌的交叉反应性,这限制了它们的特异性。周质蛋白26(BP26)是一种在[具体来源未提及]中发现的高度免疫原性抗原,已成为提高诊断特异性的有前途的替代方法。本研究旨在开发和评估一种利用抗BP26单克隆抗体的竞争性酶联免疫吸附测定(C-ELISA)用于诊断人类布鲁氏菌病,从而提供一种更准确、特异的诊断方法。
本研究通过传统的小鼠杂交瘤技术制备了抗BP26蛋白的单克隆抗体(mAb),并开发了C-ELISA方法,并与基于LPS mAb的C-ELISA方法进行比较。通过分析190份人类血清样本验证检测性能,这些样本包括徐州市疾病预防控制中心收集的95份布鲁氏菌病血清样本和95份阴性血清样本,并对使用BP26和基于LPS的方法进行布鲁氏菌病间接ELISA诊断效能进行了比较分析。
基于BP26 mAb的C-ELISA在检测人类布鲁氏菌病时灵敏度和特异性均达到100%,显著优于基于LPS mAb的C-ELISA。此外,使用BP26蛋白的间接酶联免疫吸附测定(I-ELISA)的准确率为98.95%,而LPS诊断的准确率为99.47%。这些结果表明BP26 mAb能够有效、准确地检测人类布鲁氏菌病感染。
本研究成功开发并评估了一种基于BP26蛋白的C-ELISA方法用于诊断人类布鲁氏菌病,为确定布鲁氏菌病的替代诊断抗原奠定了基础。